Masanori Terashima

Masanori Terashima

Auto-generated profile, based on publicly available information

Masanori Terashima

Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MTMasanori Terashima
Masanori Terashima
KKKoji Kitada
Koji Kitada
AOAtsushi Ochiai
Atsushi Ochiai
WIWataru Ichikawa
Wataru Ichikawa
IKIssei Kurahashi
Issei Kurahashi
FGfor the ACTS-GC Group
for the ACTS-GC Group
Purpose: EGF receptor (EGFR) and HER2 positivity are considered to be negative prognostic factors in gastric cancer. Biomarker analysis was conducted to evaluate the impact of EGFR and HER2 expression on the outcome of patients enrolled in the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC), a randomized controlled trial comparing postoperative adjuvant S-1 therapy with surgery alone in 1,059 patients with stage II/III gastric cancer. Experimental Design: Formalin-fixed, paraffin-embedded surgical specimens were retrospectively examined in 829 patients (78.3%). The effects of EGFR and HER2 positivity on survival were analyzed on the basis of the 5-year survival data from the study. EGFR positivity was defined as an immunohistochemistry (IHC) score of 3+, and HER2 positivity as an IHC score of 3+ or an IHC score of 2+ with a positive dual-color in situ hybridization status. Results: EGFR and HER2 were positive in 75 (9.0%) and 113 (13.6%) patients, respectively. The overall and relapse-free survival rates were significantly lower in EGFR-positive patients than in EGFR-negative patients, whereas they were similar in HER2-positive and HER2-negative patients. Multivariate analysis showed that EGFR positivity correlated with poor outcomes [HR = 1.504; 95% confidence interval (CI) = 1.020–2.149; P = 0.040]. Treatment with S-1 improved survival compared with surgery alone, irrespective of EGFR and HER2 status. Conclusions: EGFR positivity, but not HER2 positivity, was associated with poor patient outcomes after curative resection of stage II/III gastric cancer. There was no interaction between S-1 and EGFR or HER2 status with respect to survival outcome. Clin Cancer Res; 18(21); 5992–6000. ©2012 AACR.

31 January 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KFKeiichi Fujiya
Keiichi Fujiya
TKTaiichi Kawamura
Taiichi Kawamura
KOKatsuhiro Omae
Katsuhiro Omae
RMRie Makuuchi
Rie Makuuchi
TITomoyuki Irino
Tomoyuki Irino
MTMasanori Terashima
Masanori Terashima

16 November 2020 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
YIYoshiaki Iwasaki
Yoshiaki Iwasaki
MTMasanori Terashima
Masanori Terashima
JMJunki Mizusawa
Junki Mizusawa
HKHiroshi Katayama
Hiroshi Katayama
KNKenichi Nakamura
Kenichi Nakamura
MSMitsuru Sasako
Mitsuru Sasako

20 October 2021 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
KYKazuhiro Yoshida
Kazuhiro Yoshida
IYItaru Yasufuku
Itaru Yasufuku
MTMasanori Terashima
Masanori Terashima
SRSun Young Rha
Sun Young Rha
JBJae Moon Bae
Jae Moon Bae
C(CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO)
CONVO-GC-1 Study Group, Federation of Asian Clinical Oncology (FACO)
Aim: Much attention has been paid to conversion therapy for stage IV gastric cancer, however, its operative comorbidities and survival benefit have not yet been clarified. CONVO‐GC‐1, an international retrospective cohort study, was designed to investigate the role of conversion surgery in Japan, Korea, and China.Methods: The rate of operative complications was the primary endpoint and the overall survival (OS), according to the four‐category criteria previously published (Gastric Cancer:19; 2016), was analyzed as the secondary endpoint.Results: A total of 1206 patients underwent surgery after chemotherapy with curative intent. Operative complications were observed in 290 (24.0%) patients in all grades, including pancreatic fistula and surgical site infection. The median survival time (MST) of all resected patients was 36.7 mo (M) and those of R0, R1, and R2 resection were 56.6 M, 25.8 M, and 21.7 M, respectively. Moreover, the MST of R0 patients were 47.8 M, 116.7 M, 44.8 M in categories 1, 2, and 3, respectively, and not reached in category 4. Interestingly, the MST of P1 patients was as favorable as that of P0CY1 patients if R0 resection was achieved. The MST of patients with liver metastasis was also favorable regardless of the number of lesions, and the MST of patients with para‐aortic lymph node (LN) No 16a1/b2 metastasis was not inferior to that of patients with para‐aortic LN No 16a2/b1 metastasis.Conclusion: Conversion therapy for stage IV gastric cancer is safe and could be a new therapeutic strategy to improve the survival of patients, especially those with R0 resection.

13 October 2018 in Surgery Today
Verified
Journal Article
Closed access
PDF file
RMRie Makuuchi
Rie Makuuchi
TITomoyuki Irino
Tomoyuki Irino
YTYutaka Tanizawa
Yutaka Tanizawa
EBEtsuro Bando
Etsuro Bando
TKTaiichi Kawamura
Taiichi Kawamura
MTMasanori Terashima
Masanori Terashima

9 April 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TKTaiichi Kawamura
Taiichi Kawamura
RMRie Makuuchi
Rie Makuuchi
MTMasanori Tokunaga
Masanori Tokunaga
YTYutaka Tanizawa
Yutaka Tanizawa
EBEtsuro Bando
Etsuro Bando
MTMasanori Terashima
Masanori Terashima